pharma · Acne Vulgaris · Pruritus · VYNE
VYNE Therapeutics
Vyne Therapeutics (Israel) is a pharma organization headquartered in Bridgewater, USA. It trades on NYSE under ticker VYNE. Primary therapeutic focus areas include Acne Vulgaris, Pruritus, Rosacea, Epidermolysis Bullosa,
520 U.S. Highway 22, Suite 204, Bridgewater, NJ 08807, US HQ
2003 Founded
47 Employees
Public company Type
VYNE · NYSE Ticker
Company details
- Status
- Public
- HQ
- 520 U.S. Highway 22, Suite 204, Bridgewater, NJ 08807, US
- Founded
- 2003
- Employees
- 47
- Programs
- 30
- Drugs
- 16
- Patents
- 7
serlopitant
Phase 2 · small molecule · Prurigo Nodularis
serlopitant for Prurigo Nodularis is a Phase 2 program (small_molecule) at VYNE Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code TCP-102
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- VYNE Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Prurigo Nodularis
- Status
- completed
- Trials
- 1